Key Takeaways
- Net Profit: Rs 3,118 crore, up 2.55% year-on-year
- Revenue: Rs 14,478 crore, up 9% year-on-year
- EBITDA Margin: 31.3% with 14.9% growth
- US Milestone: Innovative medicines surpassed generics for the first time
Sun Pharmaceutical Industries reported a consolidated net profit of Rs 3,118 crore for the second quarter of FY26, marking a 2.55% increase compared to the same period last year. The company’s revenue from operations grew by nearly 9% to reach Rs 14,478 crore.
Strong Financial Performance
Sun Pharma demonstrated robust operational performance with EBITDA reaching Rs 4,527 crore, a significant 14.9% year-on-year growth. The company maintained a healthy EBITDA margin of 31.3% during the September quarter.
Managing Director Kirti Ganorkar highlighted that “India, emerging markets and the rest of the world led our growth for the period.” He also noted a landmark achievement: “US sales of innovative medicines surpassed generics for the first time during the quarter.”
Regulatory Progress and Product Pipeline
The company filed four Abbreviated New Drug Applications (ANDAs) during the quarter and received approval for five ANDAs. Sun Pharma’s portfolio currently includes 57 approved New Drug Applications (NDAs) with 14 more awaiting US FDA approval. One new NDA was filed during Q2FY26.
Market-wise Performance
India Formulations
Domestic formulation sales grew by 11% to Rs 4,735 crore, accounting for 32.9% of total consolidated sales. The company launched nine new products during the quarter, bringing the total to 15 product launches to date.
International Markets
Rest of World: Formulation sales reached $234 million, up 17.7% year-on-year, contributing 14.2% to total sales.
Emerging Markets: Sales increased by 10.9% to $325 million, representing 19.7% of total consolidated sales.
Global Innovative Medicines: This segment saw 16.4% growth to $333 million, accounting for 20.2% of total sales. The quarter also saw the US launch of Leqselvi for severe alopecia areata treatment.
API Business Performance
External sales of Active Pharmaceutical Ingredients (APIs) declined by 19.5% to Rs 4,299 million for Q2FY26. For the first half of the fiscal year, API sales stood at Rs 9,702 million, reflecting a 5.7% decrease compared to the same period last year.
